HS-10352
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for HS-10352, covering 2025-03-26 to 2025-03-26. Get the full timeline:
Most recent: Clinical Trial Update: A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients [Phase 1, Phase 2]